FCGR2A and rheumatoid arthritis: RA patients with the low-affinity FCGR2A-RR genotype had a significantly better ACR20 response (RR: 60% and HH-RH: 33.3%; p = 0.035), while EULAR good and moderate responses only showed a significant trend after 30 weeks of IFX treatment (RR: 38.1% and HH-RH: 25.0%).